OKYO News and Press, OKYO Pharma Limited From 07/31/23

LONDON and NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in t...

LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in t...

2023-07-28 17:20:26 ET OKYO Pharma ( NASDAQ: OKYO-OLD ) said on Friday that Nasdaq had notified it that for the previous 30 consecutive business days, the market value of OKYO's ordinary shares had closed below the minimum $35M requirement. OKYO shares fell 6.4% in ex...

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, t...

2023-07-28 10:11:25 ET Gainers: Reata Pharmaceuticals ( RETA ) +53% . Bluejay Diagnostics ( BJDX ) +48% . INVO Bioscience ( INVO ) +26% . OKYO Pharma ( OKYO ) +24% . BIOLASE ( BIOL ) +10% . Losers: Tonix Pharmaceutica...

OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP Second clinical indication for OK-101 which is currently in 240 patient phase 2 clinical trial to treat dry e...

LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announc...

Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain component Top-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bi...

(NewsDirect) By David Willey, Benzinga The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio (NASDAQ: ISEE). Iveric Bio’s focus is on developing innovative treatments for eye...

--News Direct-- By David Willey, Benzinga The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio (NASDAQ: ISEE). Iveric Bio’s focus is on developing innovative treatments for ...